ANZCTR search results

Given the burden of chronic pain to society and individuals and the potential to improve outcomes through adjunctive treatment, a randomised controlled trial comparing the effectiveness of multi-disciplinary pain management (PM) on its own versus multi-disciplinary pain management plus an additional treatment is planned for people with nociceptive or neuropathic dominant low back pain. We hypothesise that the additional treatment added to a pain management program will lead to some additional benefits for people with low back pain compared to a pain management program alone.

The research study is looking at what are the effects of orthodontic treatment of a small lower jaw in children. The treatment being investigated in this study is composed of an appliance (known as invisible functional appliance) that will help the lower jaw posture forward. The invisible functional appliance will be used for 9-12 months and will be compared with two other commonly used appliances to correct the small lower jaw.

This study aims to investigate whether using alternative diagnosis labels for melanoma in situ has any impact on worry/anxiety and treatment preferences for adults. Who is it for? You may be eligible for this study if you are aged 40 years or older and are in good general health without a clinically significant medical history. People who have been diagnosed with melanoma will not be eligible for this study. Study details This trial will be conducted online and no in-person visits are required. Participants who choose to enrol in this study will be asked to access an online survey via a link provided to them by email. Participants will then be presented with one of three different diagnosis scenarios where one of three labels for low-risk melanoma may be used. After reviewing this information, participants will then be asked to respond to a series of questions about their preferred choice of management for that diagnosis, their level of anxiety about that diagnosis, and their level of anxiety about that management choice. Completion of the survey is anticipated to take up to 15 minutes during a single session, no further participation is required. It is hoped this research will determine whether different diagnosis labels influence management choices and anxiety after a low-risk melanoma diagnosis.

This is a Phase 1, first-in-human (FIH), randomised, double-blind, placebo controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of single ascending doses (SAD) and multiple ascending doses (MAD) of SION-719 administered as an oral suspension in healthy participants.

This study will evaluate the safety and efficacy of Combining Oral Azacitidine and Dendritic Cell Vaccination Vididencel in maintenance for Acute Myeloid Leukemia. Who is it for? You may be eligible to join this study if you are aged 16 and above and have Acute Myeloid Leukemia in first complete remission following intensive chemotherapy, not planned for allogeneic stem cell transplant Study details: This study is part of the International AML Platform Consortium. Participants in this study will be randomly allocated (by chance) to one of two treatment groups. Participants in one group will receive the oral drug Azacitidine daily on Days 1-14 of each 28 day cycle and a course of vididencel will be administered intradermally on cycle 1 (Day 1, Day 15), Cycle 2 (Day 1, Day 15), Cycle 4 day 1, Cycle 5 day 1, and Cycle 6 day 1. Oral-Aza 300mg will continued until progression to >15% blasts or unacceptable adverse events. Participants in the other group will receive the oral drug Azacitidine daily on Days 1-14 of each 28 day cycle, continued until progression to >15% blasts or unacceptable adverse events. Patient with low blast count (5-15%) can have oral Aza dosing regimen increased to 21 days per cycle, if Investigators finds that beneficial for the patient. As part of the study, participants will have blood tests at the start of each cycle (every 28 days) and measurable residual disease testing on bone marrow samples at the end of each second cycle until cycle 6 and then end of every 3 cycles. We hope that the results from this trial will be used to help these new treatments which may be better for people with AML than what is currently available become accessible to the general population at faster than the normal process.

The key neuropathological findings of Alzheimer’s Disease are the accumulation of diffuse and neuritic amyloid plaques. In AD, it has become increasingly recognized that amyloid accumulation in the brain occurs decades before such symptoms as memory loss and personality change begin. AV-1959R vaccine is designed to induce production of anti-amyloid antibodies, that can prevent plaques formation. In this Phase I trial, the Sponsor will seek to determine the safety, tolerability, and immunogenicity of an active preventive vaccine, AV-1959R, targeting amyloid beta in healthy participants.

The primary purpose of this study to evaluate the effectiveness of behavioural sleep interventions for treatment of non-respiratory sleep disorders in children with ND. Alongside this, we hope to determine the optimal mode of delivery of treatment for non-respiratory sleep disorders in children with ND. Therefore, we developed the following two hypothesis: (i) A structured behavioural sleep intervention program will be more effective than standard clinical treatment for the management of non-respiratory sleep problems in children with ND. and (ii) Group telehealth and app delivery of a behavioural sleep intervention program will be as effective as standard clinical care for the management of non-respiratory sleep problems in children with ND.

Parental support is strongly associated with protective factors across a range of child health outcomes for trans young people. Commonly, parents report barriers to supporting their child such as lack of understanding and difficulty accessing information and support regarding gender diversity. We will provide foundational information, therapeutic support and resources for parents wait-listed with a pediatric gender diversity service, with the primary goals of increasing parental understanding, confidence, and support and the secondary goals of improving parental quality of life and delivering an acceptable intervention.

This study aims to 1) evaluate the implementation of structured Nature Walking Groups (NWG) in mental health services, 2) identify the impact of facilitated nature contact for people living with severe and persistent mental health conditions, and 3) deliver evidence-based guidelines for service providers to implement and evaluate NWGs supporting future implementation and research. The study hypothesis is that participation in structured Nature Walking Groups (NWG) within mental health services will lead to significant improvements in mental health outcomes for individuals living with severe and persistent mental health conditions, as evidenced by measured reductions in symptoms of anxiety, depression, and overall psychological distress.

The primary purpose of the study is to assess the safety and feasibility of using the Aethlon Hemopurifier in combination with anti-PD-1 therapy (pembrolizumab or nivolumab) for cancer patients with solid tumors. Who is it for? You may be eligible for this study if you are aged 18 years or older, you have been diagnosed with non-small cell lung cancer, melanoma, bladder/urinary tract cancer (urothelial cancer), renal cancer, colorectal cancer, gastric or gastroesophageal junction or esophageal cancer, head and neck cancer, cervical cancer or mesothelioma; and you have either recently begun or are going to receive treatment with pembrolizumab or nivolumab. Study details Participants who choose to enrol in this study will all receive the Aethlon Hemopurifier (HP) treatment, however depending upon the timing of your enrolment you may receive a different dose of the HP treatment. The maximum number of doses you may receive is one 4-hour treatment per day, on alternating days, for a total of up to three doses. You will continue to receive your scheduled pembrolizumab or nivolumab treatment during your participation in this study. It is hoped this research will determine the optimal dosing interval for the Aethlon Hemopurifier treatment and demonstrate that this treatment can decrease the levels of exosoms associated with cancer progression. It is also hoped that the HP treatment may improve cancer patients response to anti-PD-1 therapy (pembrolizumab or nivolumab).